Literature DB >> 10572608

Awareness of disease among Italian cancer patients: is there a need for further improvement in patient information? The Italian Group for the Evaluation of Outcomes in Oncology (IGEO).

.   

Abstract

BACKGROUND: Studies are available showing that cancer patients in southern Europe may be less well informed about their disease than patients in northern Europe and North America. PATIENTS AND METHODS: In the framework of a survey aimed at exploring the meaning of quality of life for the Italian cancer patient, carried out all over Italy in a one-week time span on 6098 consecutive patients, two visual analogue scales evaluating severity and curability of disease were also submitted to the patients. Four patterns of patients' answers were defined: very easy/difficult-to-cure disease, and not-severe/severe disease. Multifactorial analyses were performed using logistic models for each of the four responses, assuming patient characteristics, time since diagnosis and disease extent as explanatory variables.
RESULTS: Only 26% of 2088 patients with disseminated disease believed it to be 'difficult to cure', while 39% felt it to be 'easy to cure'. In the same subgroup of patients, only 47% found their disease 'severe'.
CONCLUSIONS: Authors were impressed by these unexpected results, which are therefore reported separately from the overall analysis of data, aimed at exploring the quality of life domains for the Italian cancer patient. In fact, they would suggest a great lack of awareness of the severity and curability of their disease in a large group of unselected Italian cancer patients. This may depend on various factors, including cross-cultural ones, but could also be partly related to inadequacies in the process by which the Italian patient is informed, and this should be further investigated.

Entities:  

Mesh:

Year:  1999        PMID: 10572608

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

1.  Information to cancer patients: ready for new challenges?

Authors:  Antonella Surbone
Journal:  Support Care Cancer       Date:  2008-02-22       Impact factor: 3.603

Review 2.  Conceptualizing prognostic awareness in advanced cancer: a systematic review.

Authors:  Allison J Applebaum; Elissa A Kolva; Julia R Kulikowski; Jordana D Jacobs; Antonio DeRosa; Wendy G Lichtenthal; Megan E Olden; Barry Rosenfeld; William Breitbart
Journal:  J Health Psychol       Date:  2013-10-24

3.  Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients.

Authors:  Anna Costantini; Walter F Baile; Renato Lenzi; Massimo Costantini; Vincenzo Ziparo; Paolo Marchetti; Luigi Grassi
Journal:  J Cancer Educ       Date:  2009       Impact factor: 2.037

4.  Information for patients with early-stage prostate cancer: a comparison of professionals' attitudes in Canada and Italy.

Authors:  D Feldman-Stewart; C Capirci; M D Brundage
Journal:  Support Care Cancer       Date:  2003-04-10       Impact factor: 3.603

5.  An exploratory study on the Italian patients' preferences regarding how they would like to be told about their cancer.

Authors:  Emanuela Mauri; Elena Vegni; Edoardo Lozza; Patricia A Parker; Egidio A Moja
Journal:  Support Care Cancer       Date:  2009-04-03       Impact factor: 3.603

6.  Patient perception of disease control and psychological distress.

Authors:  Eva Mazzotti; Claudia Sebastiani; Paolo Marchetti
Journal:  Cancer Manag Res       Date:  2012-09-27       Impact factor: 3.989

7.  Risk communication with Arab patients with cancer: a qualitative study of nurses and pharmacists.

Authors:  Kerry Wilbur; Alya Babiker; Maha Al-Okka; Ebaa Jumaat; Sumaya M Al Saadi Al-Yafei; Abdulqadir J Nashwan
Journal:  BMJ Open       Date:  2015-04-01       Impact factor: 2.692

8.  Medication risk communication with cancer patients in a Middle East cancer care setting.

Authors:  Kerry Wilbur; Maha Al-Okka; Ebaa Jumaat; Nesma Eissa; Merwa Elbashir; Sumaya M Al Saadi Al-Yafei
Journal:  Patient Prefer Adherence       Date:  2016-04-22       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.